Literature DB >> 30826166

Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell carcinoma.

Hiroshi Kikuchi1, Takashige Abe2, Ryuji Matsumoto1, Takahiro Osawa1, Satoru Maruyama1, Sachiyo Murai1, Nobuo Shinohara1.   

Abstract

OBJECTIVE: To evaluate the association between the RENAL nephrometry score (RNS) and tumor proliferative activity assessed by immunohistochemistry in patients with localized renal cell carcinoma.
METHODS: The current study included 145 pathological T1 (pT1) clear cell renal cell carcinomas (ccRCC). Tumor proliferative activity was assessed with the Ki67 index and microvessel density (MVD). RNS was retrospectively assessed in the present study. We divided patients into 3 groups according to RNS (RNS 4-6: low-complexity, 7-9: moderate complexity, and 10-12: high-complexity tumors) and compared the Ki67 index as well as MVD among the 3 groups. The association between the Ki67index/MVD and each component (R, E, N, A, L, h) was also evaluated.
RESULTS: There were 56 low, 84 moderate, and 5 high-complexity tumors. The median Ki67 index of all tumors was 5.34% (interquartile range: 3.28-8.57). The median Ki67 index of low, moderate, and high-complexity tumors was 3.97%, 6.39%, and 11.27%, respectively, with a significant difference among the 3 groups (Kruskal-Wallis test, P = 0.0004). On the other hand, the median MVD of low, moderate, and high-complexity tumors was 14.11%, 14.42%, and 21.22%, respectively, and there were no significant differences among the 3 groups. In terms of each RNS component, there were significant differences in the Ki67 index among the 3 groups in N (P = 0.0101) and L (P = 0.0280) components, respectively.
CONCLUSIONS: The revealed association between RNS and the Ki67 index in pT1 clear cell renal cell carcinomas further supports the previous findings that the anatomy of renal cell carcinoma is associated with the malignant potential of localized clear cell renal cell carcinoma, which may provide additional information for treatment decision.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ki67 index; Kidney; Microvessel density; Neoplasms; RENAL nephrometry score

Mesh:

Year:  2019        PMID: 30826166     DOI: 10.1016/j.urolonc.2019.02.005

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell carcinoma-the tiger in the tall grasses versus the cat in plain sight.

Authors:  Ziting Wang; Ho Yee Tiong
Journal:  Ann Transl Med       Date:  2019-07

2.  Predicting biological behaviour of newly diagnosed renal masses: a possible role of cell proliferation biomarkers?

Authors:  Riccardo Mastroianni; Aldo Brassetti; Manuela Costantini; Giuseppe Simone
Journal:  Ann Transl Med       Date:  2019-07

3.  Clinical impact of segmental renal vein invasion on recurrence in patients with clinical T1 renal cell carcinoma undergoing partial nephrectomy.

Authors:  Takashi Yoshida; Chisato Ohe; Toyonori Tsuzuki; Motohiko Sugi; Hidefumi Kinoshita; Koji Tsuta; Tadashi Matsuda
Journal:  Int J Clin Oncol       Date:  2019-09-17       Impact factor: 3.402

4.  Imaging Tool for Predicting Renal Clear Cell Carcinoma Fuhrman Grade: Comparing R.E.N.A.L. Nephrometry Score and CT Texture Analysis.

Authors:  Ran Sun; Sheng Zhao; Huijie Jiang; Hao Jiang; Yanmei Dai; Chuzhen Zhang; Song Wang
Journal:  Biomed Res Int       Date:  2021-12-23       Impact factor: 3.411

5.  New Preoperative Nomogram Using the Centrality Index to Predict High Nuclear Grade Clear Cell Renal Carcinoma.

Authors:  Zhan Feng; Shuangshuang Lou; Lixia Zhang; Liang Zhang; Wenting Lan; Minhong Wang; Qijun Shen; Zhengyu Hu; Feng Chen
Journal:  Cancer Manag Res       Date:  2019-12-31       Impact factor: 3.989

6.  Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a.

Authors:  Hailang Liu; Zhixian Wang; Ejun Peng; Zhiqiang Chen; Kun Tang; Ding Xia
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.